In vivo distribution and fractionation of indium in rats after subcutaneous and oral administration of [(114m)In]InAs.
Two in vivo experiments were carried out in this study. In the first experiment five rats were given two subcutaneous injections of [(114m)In]InAs. Major sites of accumulation were spleen, liver and kidney. The intracellular distribution of indium was examined by differential centrifugation. The cytoplasmic fraction contained most of the indium activity followed by the mitochondrial fraction. Both outcomes are in close agreement with the results obtained in previous studies. Chromatographic separations on a preparative size exclusion column were carried out. It was shown that indium was mostly bound to high molecular mass compounds in serum and in the cytoplasmic fraction of spleen, liver and kidney. In a second experiment five rats were given four oral doses of [(114m)In]InAs over a short period. Prior to this experiment the in vitro solubility of cold InAs in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) was determined using graphite furnace atomic absorption spectroscopy. In the case of the SGF only 1.3% of an InAs suspension dissolved after 48 hours incubation at 37 degrees C. InAs was not soluble in SIF. Uptake of InAs after oral administration was minimal (<1%). Due to incomplete removal of traces of [(114m)In]InAs from the gastrointestinal tract, it was impossible to calculate accurately the in vivo distribution over the different organs. As the uptake and consequently the activity in the organs were very low, no further chromatographic separations could be carried out. Considering this very low uptake, it can be concluded that InAs will not accumulate in the body after oral exposure.
Van Hulle
Marijn
M
Department of Analytical Chemistry, Ghent University, Proeftuinstraat 86, B-9000 Ghent, Belgium.
De Cremer
Koen
K
Vanholder
Raymond
R
Cornelis
Rita
R
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000818:Animals; D003593:Cytoplasm / Q000378:metabolism*; D007204:Indium / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007205:Indium Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007408:Intestinal Absorption; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008928:Mitochondria / Q000378:metabolism*; D051381:Rats; D012995:Solubility; D013054:Spectrophotometry, Atomic; D013154:Spleen / Q000378:metabolism; D013696:Temperature; D013997:Time Factors; D014018:Tissue Distribution
D007205:Indium Radioisotopes; D007204:Indium